Stay updated on Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded a Florida location to the study Locations section and removed the separate Florida Locations entry; page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedThe Publications section now clarifies that publications are provided voluntarily and relate to the study results. A revision note 'Revision: v3.3.2' was added.SummaryDifference0.1%

- Check48 days agoChange DetectedA government funding/operating status notice was removed from the page. The study details, eligibility criteria, and outcomes sections appear unchanged.SummaryDifference0.4%

- Check63 days agoChange DetectedNo significant updates to the study details or results are visible; any differences appear to be minor formatting changes, and to avoid alerts for small changes, set an alert condition.SummaryDifference0.4%

- Check91 days agoChange DetectedMajor change: page version upgraded to v3.2.0 and added a government-operating status notice; minor content addition of a medical term (Soft tissue sarcoma). Deletion of v3.1.0 confirms version update. If no other core content changes are detected, this is a partial but notable update.SummaryDifference3%

- Check98 days agoChange DetectedUpdate: version tag upgraded from v3.0.2 to v3.1.0, replacing the old revision with a new one. No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Axitinib & Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.